ZBTB16 and neoplasm: Ting et al. found that high CDH3 expression is related to EGFR-TKI resistance (Hsiao et al., 2020a); Cao et al. found that high CST1 expression can be used as a marker for recurrence and metastasis in patients with NSCLC (Cao et al., 2015); Wang et al. found that low expression of ZBTB16 can promote the survival of NSCLC tumor cells and enhance their invasiveness (Wang et al., 2013; Xiao et al., 2015).